Vagotomy

ReShape Lifesciences™ Presents Data on Proprietary Diabetes Bloc-Stim Neuromodulation™ Device at ObesityWeek®

Retrieved on: 
Thursday, November 3, 2022
Glucose, Private Securities Litigation Reform Act, Diet, Type 2 diabetes, Alloxan, Weight loss, SAN, CA, Obesity, PG, Risk, Industry, GLOBE, Vagotomy, SBIR, Ramakanta Panda, FDA, Safety, Metabolic disorder, Patient, Nasdaq, Plasma, Oxidative stress, Marketing, Roy Taylor (scientist), Research, Vagus nerve, Type 2, Anatomy, Collection, Annual report, U.S. Securities and Exchange Commission, Insulin, Stomach, Pancreas, Diabetes, Forward-looking statement, Reshaping Cultural Policies, CV, Liver, Technology, Security (finance), NIH, Hypoglycemia, SD, Insulin resistance, Ligation, Person, Miniature pig, Pharmaceutical industry, Medical device, T2DM

Despite medication, surgery and diet, type 2 diabetes remains challenging to effectively treat, stated Jonathan Waataja, Director of Research at ReShape Lifesciences.

Key Points: 
  • Despite medication, surgery and diet, type 2 diabetes remains challenging to effectively treat, stated Jonathan Waataja, Director of Research at ReShape Lifesciences.
  • Previously, the area under the curve of oral glucose tolerance tests (OGTTs) was calculated to quantify glycemic control.
  • The opportunity to present such compelling data on our proprietary DBSN device at this industry conference is a testament to the market potential of the technology to treat type 2 diabetes, stated Paul F. Hickey, President and Chief Executive Officer of ReShape Lifesciences.
  • The investigational Diabetes Bloc-Stim Neuromodulation (DBSN) system utilizes a proprietary vagus nerve block and stimulation technology platform for the treatment of Type 2 diabetes and metabolic disorders.

Enterin Announces Publication of Exciting Discoveries About the Enterin Nervous System

Retrieved on: 
Friday, November 19, 2021
Patient, Bupropion, Scientific Reports, Vagus nerve, Lists of diseases, Psychosis, CSO, Dopamine, McMaster University Medical School, Brain, Diabetes, Dementia, McMaster University, Sertraline, ENS, Human, Central nervous system, GI, Alzheimer's disease, Neurodegeneration, Sleep, Mouse, Norepinephrine, Neurogenesis, Selective serotonin reuptake inhibitor, Research, FRCP, Nervous system, Parkinson's disease, Obesity, GLOBE, Infection, Appetite, Enteric nervous system, Depression, Vagotomy, CNS, Fluoxetine, CMO, Pharmaceutical industry, Medical device, Medical imaging

Vast numbers of sensory signals originating in the gut are captured by the enteric nervous system (ENS) and conveyed to the brain via the vagus nerve.

Key Points: 
  • Vast numbers of sensory signals originating in the gut are captured by the enteric nervous system (ENS) and conveyed to the brain via the vagus nerve.
  • As a consequence, damage either to the ENS or the vagus nerve can have significant GI as well as neuropsychiatric consequences.
  • Serotonin (5-hydroxytryptamine; 5-HT) is an important neurotransmitter both in the central nervous system (CNS) and the ENS.
  • Serotonin is involved in GI-related functions such as neurogenesis, epithelial repair, GI secretions, and gut motility.